Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by HENRY MARK KUERER and AYSEGUL A SAHIN.
HENRY MARK KUERER
Connection Strength
1.485
AYSEGUL A SAHIN
  1. DCIS Margins and Breast Conservation: MD Anderson Cancer Center Multidisciplinary Practice Guidelines and Outcomes. J Cancer. 2017; 8(14):2653-2662.
    View in: PubMed
    Score: 0.152
  2. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy. Cancer. 2006 Jan 01; 106(1):42-50.
    View in: PubMed
    Score: 0.068
  3. The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer. Clin Cancer Res. 2005 Dec 01; 11(23):8398-402.
    View in: PubMed
    Score: 0.067
  4. Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy. Cancer. 2005 Aug 15; 104(4):676-81.
    View in: PubMed
    Score: 0.066
  5. Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys. 2004 Aug 01; 59(5):1337-42.
    View in: PubMed
    Score: 0.061
  6. Intraoperative margin assessment reduces reexcision rates in patients with ductal carcinoma in situ treated with breast-conserving surgery. Am J Surg. 2003 Oct; 186(4):371-7.
    View in: PubMed
    Score: 0.058
  7. Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma. Cancer. 2002 Jun 15; 94(12):3107-14.
    View in: PubMed
    Score: 0.053
  8. Axillary lymph node cellular immune response to HER-2/neu peptides in patients with carcinoma of the breast. J Interferon Cytokine Res. 2002 May; 22(5):583-92.
    View in: PubMed
    Score: 0.052
  9. Multidisciplinary management of breast cancer concurrent with pregnancy. J Am Coll Surg. 2002 Jan; 194(1):54-64.
    View in: PubMed
    Score: 0.051
  10. Prospective Registry Trial Assessing the Use of Magnetic Seeds to Locate Clipped Nodes After Neoadjuvant Chemotherapy for Breast Cancer Patients. Ann Surg Oncol. 2021 Aug; 28(8):4277-4283.
    View in: PubMed
    Score: 0.048
  11. Effectiveness and Safety of Magseed-localization for Excision of Breast Lesions: A Prospective, Phase IV Trial. Ann Surg Open. 2020 Dec; 1(2).
    View in: PubMed
    Score: 0.048
  12. Identification and evaluation of axillary sentinel lymph nodes in patients with breast carcinoma treated with neoadjuvant chemotherapy. Am J Surg Pathol. 2000 Sep; 24(9):1266-72.
    View in: PubMed
    Score: 0.047
  13. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg. 1999 Jul; 230(1):72-8.
    View in: PubMed
    Score: 0.043
  14. Digital Breast Tomosynthesis for Intraoperative Margin Assessment during Breast-Conserving Surgery. Ann Surg Oncol. 2019 Jun; 26(6):1720-1728.
    View in: PubMed
    Score: 0.042
  15. Multidisciplinary Intraoperative Assessment of Breast Specimens Reduces Number of Positive Margins. Ann Surg Oncol. 2018 Oct; 25(10):2932-2938.
    View in: PubMed
    Score: 0.040
  16. Expanding Implementation of ACOSOG Z0011 in Surgeon Practice. Clin Breast Cancer. 2018 08; 18(4):276-281.
    View in: PubMed
    Score: 0.038
  17. Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy. JAMA Oncol. 2016 Apr; 2(4):508-16.
    View in: PubMed
    Score: 0.034
  18. Residual tumor thickness at the tumor-normal tissue interface predicts the recurrence-free survival in patients with liver metastasis of breast cancer. Ann Diagn Pathol. 2014 Oct; 18(5):266-70.
    View in: PubMed
    Score: 0.031
  19. Locoregional recurrence risk for patients with T1,2 breast cancer with 1-3 positive lymph nodes treated with mastectomy and systemic treatment. Int J Radiat Oncol Biol Phys. 2014 Jun 01; 89(2):392-8.
    View in: PubMed
    Score: 0.030
  20. American College of Surgeons Oncology Group (ACOSOG) Z0011: impact on surgeon practice patterns. Ann Surg Oncol. 2012 Oct; 19(10):3144-51.
    View in: PubMed
    Score: 0.027
  21. Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system. J Clin Oncol. 2011 Dec 10; 29(35):4654-61.
    View in: PubMed
    Score: 0.025
  22. Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. Cancer. 2012 May 01; 118(9):2385-93.
    View in: PubMed
    Score: 0.025
  23. Multidisciplinary considerations in the implementation of the findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 study: a practice-changing trial. Ann Surg Oncol. 2011 Sep; 18(9):2407-12.
    View in: PubMed
    Score: 0.025
  24. Delays in primary surgical treatment are not associated with significant tumor size progression in breast cancer patients. Ann Surg. 2011 Jul; 254(1):119-24.
    View in: PubMed
    Score: 0.025
  25. Lymphovascular invasion and lobular histology are associated with increased incidence of isolated tumor cells in sentinel lymph nodes from early-stage breast cancer patients. Ann Surg Oncol. 2008 Dec; 15(12):3369-77.
    View in: PubMed
    Score: 0.020
  26. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys. 2007 Jul 15; 68(4):1004-9.
    View in: PubMed
    Score: 0.018
  27. Role for intraoperative margin assessment in patients undergoing breast-conserving surgery. Ann Surg Oncol. 2007 Apr; 14(4):1458-71.
    View in: PubMed
    Score: 0.018
  28. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg. 2006 Feb; 243(2):257-64.
    View in: PubMed
    Score: 0.017
  29. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol. 2005 Dec 20; 23(36):9304-11.
    View in: PubMed
    Score: 0.017
  30. Improving local control with breast-conserving therapy: a 27-year single-institution experience. Cancer. 2005 Jul 01; 104(1):20-9.
    View in: PubMed
    Score: 0.016
  31. Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys. 2005 Jun 01; 62(2):351-7.
    View in: PubMed
    Score: 0.016
  32. Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. Cancer. 2005 Apr 15; 103(8):1581-6.
    View in: PubMed
    Score: 0.016
  33. Lower and central tumor location correlates with lymphoscintigraphy drainage to the internal mammary lymph nodes in breast carcinoma. Cancer. 2005 Apr 01; 103(7):1323-9.
    View in: PubMed
    Score: 0.016
  34. Breast conservation after neoadjuvant chemotherapy. Cancer. 2005 Feb 15; 103(4):689-95.
    View in: PubMed
    Score: 0.016
  35. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol. 2004 Dec 01; 22(23):4691-9.
    View in: PubMed
    Score: 0.016
  36. Contralateral prophylactic mastectomy. Predictors of significant histologic findings. Cancer. 2004 Nov 01; 101(9):1977-86.
    View in: PubMed
    Score: 0.016
  37. Factors predictive of having four or more positive axillary lymph nodes in patients with positive sentinel lymph nodes: implications for selection of radiation fields. Int J Radiat Oncol Biol Phys. 2004 Jul 15; 59(4):1074-9.
    View in: PubMed
    Score: 0.015
  38. Breast conservation after neoadjuvant chemotherapy: the MD Anderson cancer center experience. J Clin Oncol. 2004 Jun 15; 22(12):2303-12.
    View in: PubMed
    Score: 0.015
  39. Stimulation of cells from a non-invaded and an invaded lymph node with a HER-2+ tumor with peptides corresponding to T-cell epitopes E75 and G89 induced expansion of central memory cells (TCM) from the metastasis-negative lymph nodes. Int J Oncol. 2004 Jun; 24(6):1413-8.
    View in: PubMed
    Score: 0.015
  40. T3 disease at presentation or pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy. Int J Radiat Oncol Biol Phys. 2004 May 01; 59(1):138-45.
    View in: PubMed
    Score: 0.015
  41. Histologic localization of sentinel lymph node metastases in breast cancer. Am J Surg Pathol. 2003 Mar; 27(3):385-9.
    View in: PubMed
    Score: 0.014
  42. Global gene expression changes during neoadjuvant chemotherapy for human breast cancer. Cancer J. 2002 Nov-Dec; 8(6):461-8.
    View in: PubMed
    Score: 0.014
  43. Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy. Int J Radiat Oncol Biol Phys. 2002 Jul 15; 53(4):880-8.
    View in: PubMed
    Score: 0.013
  44. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 2000 Oct 15; 18(20):3480-6.
    View in: PubMed
    Score: 0.012
  45. Ductal carcinoma-in-situ: long-term results of breast-conserving therapy. Ann Surg Oncol. 2000 Oct; 7(9):656-64.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.